- Top of page
- Dendritic cells
- DC interactions with IVIg
- DC and cytokines
- DC–NK cell interactions
- Do IVIg-DC promote Treg cells?
- What is the molecular target of IVIg?
- Disclosure of Conflict of Interests
Summary. Intravenous immunoglobulin (IVIg) is used to treat an ever-increasing number of autoimmune diseases. While the exact mechanism of action of IVIg has remained elusive, many theories have been suggested, including mononuclear phagocytic system blockade, autoantibody neutralization by anti-idiotype antibodies, accelerated pathogenic autoantibody clearance by saturation of the neonatal Fc receptor, cytokine modulation and complement neutralization. More recently, a key role for dendritic cells (DC) in the amelioration of autoimmunity by IVIg has been suggested. Here we will focus on the role that DC may play in IVIg function using data from both mouse and human studies.